• October 3, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a fourth quarter 2019 dividend payable to holders of the company’s common stock of $0.164 per share. The dividend is to be paid on Monday, Dec. 2, 2019, to holders of record on Tuesday, Oct. 22, 2019. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetismore...
  • October 3, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that Kristin Peck will succeed Juan Ramón Alaix as Chief Executive Officer, effective January 1, 2020, and join the Board of Directors, effective immediately. Alaix, who has been CEO of Zoetis since its formation in 2012, has decided to retire as CEO effective December 31, 2019. He will act as an advisor on the leadership transition through December 31, 2020. Peck currently serves as Executive Vice President andmore...
  • September 30, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 7, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2019 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-more...
  • September 20, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted marketing authorisation for Simparica Trio™ (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations. The granting of the marketing authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use on Julymore...
  • September 9, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that its scientists presented positive efficacy data for the company’s investigational, triple combination parasiticide product at the 2019 Triennial meeting of the American Heartworm Society (AHS) in New Orleans, La. Zoetis is developing a triple combination product containing sarolaner, moxidectin and pyrantel that is administered orally once a month as a preventative for heartworm disease and to treat and control ticks, fleas,more...
  • September 4, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 19, 2019, in London, England. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics, will represent the company and respond to questions from analysts. He is scheduled to present at 11:10 a.m. ET (4:10 p.m. London timemore...
  • August 15, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, Sept. 10, 2019, in New York, N.Y. Glenn David, Executive Vice President and Chief Financial Officer, and Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, will represent the company and respond to questions from analysts. They are scheduled to present at 12:20 p.m. ET. Investors andmore...
  • August 14, 2019
    PARSIPPANY, N.J. & BUELLTON, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the completion of the acquisition of Platinum Performance, a privately-held nutrition-focused animal heath company, after fulfilling all closing requirements. The acquisition was first announced on July 22 and financial terms of the transaction are not being disclosed. “We are pleased to welcome the Platinum Performance team to Zoetis and together expand on the success of their high-quality,more...
  • August 6, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the second quarter of 2019 and raised its guidance for full year 2019. The company reported revenue of $1.5 billion for the second quarter of 2019, an increase of 9% compared with the second quarter of 2018. Net income for the second quarter of 2019 was $371 million, or $0.77 per diluted share, a decrease of 3%, on a reported basis. Adjusted net income1 for the second quarter of 2019 was $more...
  • July 22, 2019
    PARSIPPANY, N.J. & BUELLTON, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced it has entered into an agreement to acquire Platinum Performance, a privately held, nutrition-focused animal health company. Platinum’s premium nutritional product formulas and unique approach to the field of scientific wellness for horses, dogs and cats will further strengthen and diversify Zoetis’ portfolio in the equine and petcare markets. Financial terms of the transaction are not beingmore...